“We’ve made great strides treating melanoma at Fox Chase and have built one of the most comprehensive multidisciplinary teams in the region—an expertise recognized nationally and internationally,” says Jeffrey M. Farma, MD, FACS, Chair and Professor, Department of Surgery, Fox Chase Cancer Center. “I’m thrilled to bring TIL (tumor-infiltrating lymphocyte) therapy to our metastatic melanoma patients who are not responding to their first-line treatment—a cellular therapy which requires critical timing and a highly specialized multidisciplinary team to deliver it.”
